| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7506307 | Drug and Alcohol Dependence | 2014 | 6 Pages |
Abstract
The outcomes of the recent ADF labeling applications for OxyContin® (Tier 3 approval) and Opana® (non-approval) suggest that the threshold for ADF labeling will be appropriately high. The presented findings indicate that ADF technologies can be a critical component of a comprehensive strategy to promote the safe and effective use of OpAs.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Louis Alexander, Richard O. Mannion, Brianne Weingarten, Richard J. Fanelli, Gary L. Stiles,